From Pulse 2.0 · Amit Chowdhry · · 50s
Merck Acquires Silence Therapeutics
Merck buys Silence Therapeutics for $1.3 billion to boost rare disease treatments.
In brief
Merck buys Silence Therapeutics for $1.3 billion to boost rare disease treatments. Merck acquires Silence Therapeutics for $1.3 billion to advance rare disease therapies using siRNA technology. Originally reported by Pulse 2.0.
Merck Acquires Silence Therapeutics
Merck has agreed to buy Silence Therapeutics for about $1.3 billion in an all-cash transaction.
Shareholder Deal Details
Silence shareholders receive $20.00 per American Depositary Share, equivalent to $6.6667 per ordinary share.
Premium Over Market
The deal offers a 130% premium to Silence’s ADS closing price on October 16, 2026, and an 82% premium to its 30-day volume-weighted average price.
Divesiran Phase 2 Data
Silence’s Divesiran shows potentially best-in-class results for polycythemia vera in Phase 2 trials.
Merck’s Strategy
Merck aims to expand in rare diseases using external innovation to strengthen its pharmaceutical pipeline.
The big picture
Merck acquires Silence Therapeutics for $1.3 billion to advance rare disease therapies using siRNA technology.
